



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

: Attn: BOX CPA

Koichi ISHIGURO et al.

: Docket No. 01416/OP551-PC-US

Serial No. 09/142,613

: Group Art Unit 1647

Filed April 19, 1999

: Examiner S. Turner

ANTI-PHOSPHORYLATED TAU PROTEIN
ANTIBODIES AND METHODS FOR
DETECTING ALZHEIMER'S DISEASE WITH
THE USE OF THE SAME

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEES FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975

RECEIVED
DEC 12 2001
TECH CENTER 160012900

PATENT OFFICE FEE TRANSMITTAL FORM

Assistant Commissioner for Patents,
Washington, DC 20231

Sir:

Attached hereto is a check in the amount of \$1,038.00 to cover Patent Office fees relating to filing the following attached papers:

Continued Prosecution Application (CPA) \$908.00

Suspension of Action \$130.00


A duplicate copy of this paper is being submitted for use in the Accounting Division, Office of Finance.

The Commissioner is authorized to charge any deficiency or to credit any overpayment associated with this communication to Deposit Account No. 23-0975, with the EXCEPTION of deficiencies in fees for multiple dependent claims in new applications.

Respectfully submitted,

Koichi ISHIGURO et al.

By


Lee Cheng
Registration No. 40,949
Attorney for Applicants

LC/gtn
WENDEROTH, LIND & PONACK, L.L.P.
2033 K St., N.W., Suite 800
Washington, D.C. 20006-1021
Telephone (202) 721-8200
December 10, 2001

[Check No. 47851]

98_0997A

421

RECEIVED
DEC 1 2 2001
TECHNICAL CENTER 1600/2910

Revised PTO/SB/29 (02/01)

PIPE
DEC 1 0 2001
PATENT & TRADEMARK OFFICE

CONTINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL

Submit an original, and a duplicate for fee processing
(Only for Continuation or Divisional applications under 37 CFR 1.53(d))
CHECK BOX, if applicable
[] DUPLICATE

Address to: Assistant Commissioner for Patents Box CPA Washington, DC 20231	Attorney Docket No.	01416/OP551-PC-US
	First Named Inventor	Koichi ISHIGURO et al.
	Express Mail Label No.	
	Total Pages	

This is a request for a ☒ continuation or ☐ divisional application under 37 CFR 1.53(d) (continued prosecution application (CPA)) of prior application number **09/142,613**, filed on **April 19, 1999**, entitled **ANTI-PHOSPHORYLATED TAU PROTEIN ANTIBODIES AND METHODS FOR DETECTING ALZHEIMER'S DISEASE WITH THE USE OF THE SAME**.

NOTES

FILING QUALIFICATIONS: The prior application identified above must be a nonprovisional application that is either: (1) complete as defined by 37 CFR 1.51(b), or (2) the national stage of an international application in compliance with 35 U.S.C. 371. Effective May 29, 2000, a CPA may only be filed in a utility or a plant application if the prior nonprovisional application was filed before May 29, 2000. A CPA may be filed in a design application regardless of the filing date of the prior application.

C-I-P NOT PERMITTED: A continuation-in-part application cannot be filed as a CPA under 37 CFR 1.53(d), but must be filed under 37 CFR 1.53(b).

EXPRESS ABANDONMENT OF PRIOR APPLICATION: The filing of this CPA is a request to expressly abandon the prior application as of the filing date of the request for a CPA. 37 CFR 1.53(b) must be used to file a continuation, divisional, or continuation-in-part of an application that is not to be abandoned.

ACCESS TO PRIOR APPLICATION: The filing of this CPA will be construed to include a waiver of confidentiality by the applicant under 35 USC 122 to the extent that any member of the public who is entitled under the provisions of 37 CFR 1.14 to access to, copies of, or information concerning, the prior application may be given similar access to, copies of, or similar information concerning the other application or applications in the file jacket.

35 USC 120 STATEMENT: In a CPA, no reference to the prior application is needed in the first sentence of the specification and none should be submitted. If a sentence referencing the prior application is submitted, it will not be entered. A request for a CPA is the specific reference required by 35 USC 120 and to every application assigned the application number identified in such request, 37 CFR 1.78(a).

1. <input type="checkbox"/>	Enter the unentered amendment previously filed on under 37 CFR 1.116 in the prior nonprovisional application.	THE COMMISSIONER IS AUTHORIZED TO CHARGE ANY DEFICIENCY IN THE FEES FOR THIS PAPER TO DEPOSIT ACCOUNT NO. 23-0975
2. <input type="checkbox"/>	A preliminary amendment is enclosed.	
3. <input type="checkbox"/>	This application is filed by fewer than all the inventors named in the prior application, 37 CFR 1.53(d)(4). a. <input type="checkbox"/> DELETE the following inventor(s) named in the prior nonprovisional application: _____ b. <input type="checkbox"/> The inventor(s) to be deleted are set forth on a separate sheet attached hereto.	
4. <input type="checkbox"/>	A new power of attorney or authorization of agent (PTO/SB/81) is enclosed.	
5. <input type="checkbox"/>	Information Disclosure Statement (IDS) is enclosed: a. <input type="checkbox"/> PTO-1449 b. <input type="checkbox"/> Copies of IDS Citations	

CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(c))	13 - 20 =		0 x \$18 =	\$0.00
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	5 - 3 =		0 x \$32 =	\$168.00
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(d))			+ \$280 =	\$
				BASIC FEE (37 CFR 1.16(e))	\$740.00
			Total of above Calculations =		\$908.00
			Reduction by 50% for filing by small entity (Note 37 CFR 1.9, 1.27, 1.28):		\$
			TOTAL =		\$908.00

6. ☐ Small entity status:

- a. ☐ Small Entity Statement is hereby asserted.
b. ☐ Is no longer claimed.

7. ☒ The Commissioner is hereby authorized to credit overpayments or charge the following fees to DepositAccount No. 23-0975

- a. ☒ Fees required under 37 CFR 1.16.
b. ☒ Fees required under 37 CFR 1.17.
c. ☐ Fees required under 37 CFR 1.18.

8. ☒ A check in the amount of \$1,038.00 is enclosed.9. ☒ Applicants request suspension of action under 37 CFR 1.103(b) for a period of three months (not to exceed 3 months) and the fee under 37 CFR 1.17(i) is enclosed.10. ☒ Return Receipt Postcard.11. ☒ Other: Preliminary Remarks are attached herewith.

NOTE: The prior application's correspondence address will carry over to this CPA UNLESS a new correspondence address is provided below.

10. NEW CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Labelor ☐ New correspondence address below

(Insert Customer No. or Attach bar code label here)

12. CORRESPONDENCE ADDRESS



000513


PATENT TRADEMARK OFFICE

By: 

Lee Cheng
Registration No. 40,949

WENDEROTH, LIND & PONACK, L.L.P.
2033 "K" Street, N.W., Suite 800
Washington, D.C. 20006-1021
Phone: (202) 721-8200
Fax: (202) 721-8250

December 10, 2001



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : **ATTN: BOX CPA**
Koichi ISHIGURO et al. : Docket No. 01416/OP551-PC-US
Serial No. 09/142,613 : Group Art Unit 1647
Filed April 19, 1999 : Examiner S. Turner

ANTI-PHOSPHORYLATED TAU PROTEIN :
ANTIBODIES AND METHODS FOR
DETECTING ALZHEIMER'S DISEASE
WITH THE USE OF THE SAME

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEES FOR THIS PAPER TO DEPOSIT
ACCOUNT NO. 23-0975

PRELIMINARY REMARKS

Assistant Commissioner for Patents,
Washington, D.C. 20231

Sir:

Applicants intend to file a preliminary paper in the new application responding to the grounds of rejection in the last Official Action.

The Examiner is kindly requested to postpone the issuance of a first Official Action in the new application while Applicants prepare this preliminary paper.


It would be very helpful to the Applicants if the Examiner would provide the Applicants' undersigned representative with an indication of the Examiner's deadline for issuing a first

Official Action, if the preliminary paper has not been filed by the time the Examiner takes up the application for examination.

Respectfully submitted,

Koichi ISHIGURO et al.

By: _____


Lee Cheng

Registration No. 40,949

Attorney for Applicants

LC/gtn
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
December 10, 2001